NCT03397706 2025-03-20Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesViracta Therapeutics, Inc.Phase 1/2 Completed64 enrolled 31 charts
NCT00992732 2011-08-01Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative DisordersHemaQuest Pharmaceuticals Inc.Phase 2 Terminated1 enrolled